Reshape Lifesciences Stock Analysis

ReShape Stock Analysis Notes

The company has price-to-book ratio of 1.14. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. ReShape Lifesciences recorded earning per share (EPS) of 76.2. The entity last dividend was issued on the 25th of July 2019. The firm had 1:58 split on the 23rd of September 2024. ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California. Reshape Lifesciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 47 people. To find out more about ReShape Lifesciences contact Dan Gladney at 949 429 6680 or learn more at https://www.reshapelifesciences.com.

ReShape Lifesciences Investment Alerts

ReShape Lifesciences Upcoming and Recent Events

ReShape Largest EPS Surprises

View All Earnings Estimates

ReShape Lifesciences Environmental, Social, and Governance (ESG) Scores

ReShape Stock Institutional Investors

Note, although ReShape Lifesciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

ReShape Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.64 M.

ReShape Profitablity

The company has Profit Margin (PM) of (1.12) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.05) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.05.

Management Efficiency

ReShape Lifesciences has return on total asset (ROA) of (0.6346) % which means that it has lost $0.6346 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8459) %, meaning that it created substantial loss on money invested by shareholders. ReShape Lifesciences' management efficiency ratios could be used to measure how well ReShape Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.29 in 2025. Return On Capital Employed is likely to drop to -2.57 in 2025. At this time, ReShape Lifesciences' Total Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 4 M in 2025, whereas Other Assets are likely to drop slightly above 111.4 K in 2025.

Technical Drivers

As of the 17th of February 2025, ReShape Lifesciences holds the Market Risk Adjusted Performance of (0.92), coefficient of variation of (438.26), and Risk Adjusted Performance of (0.15). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of ReShape Lifesciences, as well as the relationship between them. Please check ReShape Lifesciences risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and kurtosis to decide if ReShape Lifesciences is priced some-what accurately, providing market reflects its current price of 2.33 per share. Please also confirm ReShape Lifesciences jensen alpha, which is currently at (1.14) to check out the company can sustain itself at a future point.

ReShape Lifesciences Price Movement Analysis

ReShape Lifesciences Insider Trading Activities

ReShape Lifesciences Outstanding Bonds

ReShape Lifesciences Predictive Daily Indicators

ReShape Lifesciences Corporate Filings

ReShape Lifesciences Forecast Models

ReShape Lifesciences' time-series forecasting models are one of many ReShape Lifesciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ReShape Lifesciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how ReShape Lifesciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ReShape shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ReShape Lifesciences. By using and applying ReShape Stock analysis, traders can create a robust methodology for identifying ReShape entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ReShape analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ReShape analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

ReShape Lifesciences stock analysis indicators help investors evaluate how ReShape Lifesciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ReShape Lifesciences shares will generate the highest return on investment. By understating and applying ReShape Lifesciences stock analysis, traders can identify ReShape Lifesciences position entry and exit signals to maximize returns.

When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.